NR
Nurix Therapeutics, Inc.
NRIX · NASDAQ
$25.44 -1.03% (-$0.27)
1M -3.16%
Market Cap $2.64B
P/E Ratio -
Div. Yield -
ROE 76.09%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.56x
P/S 71.81x
PEG N/A
Growth
100 /100
Growing Book val. growth 21.05%
Rev. growth 29.55%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 828.28%
Op. margin 982.37%
Gross margin 165.51%
Quality
1 /100
Poor Asset turnover 0.07x
ROA 63.74%
ROIC 77.32%
Debt
100 /100
Low Current ratio 6.34x
Debt/Equity 0.14x
Net debt/EBITDA N/A
Stability
29 /100
Unstable Profitable years 0
EPS volatility 20.75%
Beta 1.80x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na NRIX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Arthur T. Sands
Employees
317
Headquarters
Brisbane
Nadcházející události
08 ŘÍJ
Earnings
Upcoming earnings report